Enzychem Lifesciences Corporation (183490)

Overview

Enzychem Lifesciences Corporation is a biopharmaceutical entity focused on the discovery, development, and commercialization of novel small molecule therapeutics. It targets a range of diseases where patient needs are largely unmet, specifically in the realms of oncology, inflammation, and severe respiratory conditions. Established in 1999, Enzychem Lifesciences has positioned itself as a pioneering force in the medical sphere, dedicated to bridging the gap between groundbreaking scientific discoveries and their practical applications in patient care. With its headquarters in Seoul, South Korea, the company leverages its strategic location in one of Asia's leading biotech hubs to innovate and expand its reach to patients globally.

Products and Services

• EC-18 for Fibrotic Diseases and Severe Respiratory Diseases

Enzychem Lifesciences is at the forefront of developing EC-18, an oral small molecule therapeutic with versatile potential applications. In the realm of fibrotic diseases, EC-18 is being studied for its efficacy in treating conditions such as nonalcoholic steatohepatitis (NASH), a serious and progressive liver disease. Beyond its application in fibrosis, EC-18 is also under development as a potential therapy for severe respiratory diseases, including as a novel treatment option for COVID-19. This exemplifies the company's commitment to addressing pandemic-related health crises and its capability to rapidly respond to emerging global health threats.